DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Synercid (Quinupristin / Dalfopristin Injection) - Published Studies

 
 



Synercid Related Published Studies

Well-designed clinical trials related to Synercid (Quinupristin / Dalfopristin)

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. [2004.04]

Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. [2002.01]

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. [2000.03]

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. [1999.08]

Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. [1999.03]

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. [1997.05]

Well-designed clinical trials possibly related to Synercid (Quinupristin / Dalfopristin)

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. [2012]

A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. [1992.07]

Other research related to Synercid (Quinupristin / Dalfopristin)

Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. [2010.07]

Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. [2009.12]

In vitro combinations of five intravenous antibiotics with dalfopristin-quinupristin against Staphylococcus aureus in a 3-dimensional model. [2008.12]

Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. [2008.02]

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. [2008.01.01]

Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium. [2007.06]

Effect of quinupristin/dalfopristin on 3T3 and Eahy926 cells in vitro in comparison to other antimicrobial agents with the potential to induce infusion phlebitis. [2007.06]

Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin's lymphoma. [2006.12]

[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium] [2006.09]

Nosocomial spondylodiskitis with epidural abscess and CSF fistula cured with quinupristin/dalfopristin and linezolid. [2006.06]

The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). [2006.01.20]

A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting. [2005.12]

Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. [2005.10]

In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections. [2005.02]

In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci. [2004.12]

Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. [2004.11]

Use of quinupristin/dalfopristin in a critical patient with a methicillin-resistant Staphilococcus aureus infection. [2004.10]

Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. [2004.09]

Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. [2004.06]

Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. [2004.06]

Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. [2004.05]

Clinical pharmacokinetics of quinupristin/dalfopristin. [2004]

Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. [2003.10]

Quinupristin/dalfopristin-induced Sweet's syndrome. [2003.09]

Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin. [2003.08]

Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. [2003.08]

Quinupristin-dalfopristin and linezolid: evidence and opinion. [2003.02.15]

Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. [2003.02]

Emergence of resistance of vancomycin-resistant Enterococcus faecium in a thermal injury patient treated with quinupristin-dalfopristin and cultured epithelial autografts for wound closure. [2002.11]

Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. [2002.10]

Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report. [2002.10]

Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. [2002.09]

Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics. [2002.09]

Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. [2002.09]

Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. [2002.07]

Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. [2002.04]

[Synercid emergency prescription program. The French experience] [2002.02.23]

Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. [2002.01]

Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. [2002]

Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. [2001.12.01]

Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. [2001.12.01]

[Experimental models: interaction of Synercid with other anti-Gram positive agents] [2001.09.08]

[Experimental models: interactions Synercid and beta-lactam antibiotics] [2001.09.08]

[Epidemiological context: microbiological value of Synercid] [2001.09.08]

Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. [2001.06]

Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients: correlation with available liver biopsy results. [2001.06]

Successful administration of quinupristin/dalfopristin in the outpatient setting. [2001.05]

Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae. [2001.05]

Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials. [2001.05]

[Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin] [2001.04]

Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers. [2001.04]

Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. [2001.04]

Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. [2001.03]

Arthralgias and myalgias related to quinupristin-dalfopristin administration. [2001.02.15]

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study. [2001.02]

Quinupristin/dalfopristin: a therapeutic review. [2001.01]

Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. [2001.01]

Quinupristin-dalfopristin: an overview. [2000.12]

In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci. [2000.11]

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. [2000.11]

Synercid Aventis. [2000.10]

Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. [2000.08]

Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. [2000.07]

Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. [2000.05]

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. [2000.05]

Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program. [2000.04]

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. [1999.12]

Safety and tolerability of quinupristin/dalfopristin: administration guidelines. [1999.09]

Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. [1999.09]

Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. [1999.09]

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. [1999.08]

Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. [1999.01]

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. [1998.10]

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. [1998.07]

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. [1998.05.29]

RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium. [1998.05]

In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. [1998.03]

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci. [1997.11]

Life-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: cure with chloramphenicol and quinupristin/dalfopristin (RP 59500). [1997.07]

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. [1997.05]

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. [1997.05]

Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis. [1997.05]

Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. [1997.05]

Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. [1997.05]

Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. [1997.05]

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. [1997.05]

Interaction between quinupristin/dalfopristin and cyclosporine. [1997.05]

Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. [1997.05]

In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. [1996.12]

Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination. [1996.09.01]

Quinupristin-dalfopristin. [1996.09]

Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin. [1996.08]

Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin. [1996.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017